Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study

  1. Ruíz-Borrego, M.
  2. Guerrero-Zotano, A.
  3. Bermejo, B.
  4. Ramos, M.
  5. Cruz, J.
  6. Baena-Cañada, J.M.
  7. Cirauqui, B.
  8. Rodríguez-Lescure, Á.
  9. Alba, E.
  10. Martínez-Jáñez, N.
  11. Muñoz, M.
  12. Antolín, S.
  13. Álvarez, I.
  14. Del Barco, S.
  15. Sevillano, E.
  16. Chacón, J.I.
  17. Antón, A.
  18. Escudero, M.J.
  19. Ruiz, V.
  20. Carrasco, E.
  21. Martín, M.
  22. Seguí, M.A.
  23. Ayala, F.
  24. de la Haba, J.
  25. Martínez, P.
  26. González, S.
  27. Lahuerta, A.
  28. Toral, J.C.
  29. de Dueñas, E.M.
  30. Florián, J.
  31. Godes, M.J.
  32. Llorca, C.
  33. Blancas, I.
  34. Jara, C.
  35. Morales, S.
  36. Arcusa, A.
  37. Martínez, A.
  38. Vicente, E.
  39. de Juan, A.
  40. Rodríguez, M.
  41. García, M.
  42. García, P.
  43. Bayo, J.L.
  44. Carañana, V.
  45. Casinello, J.
  46. Jolis, L.
  47. Gil, M.
  48. Cañabate, C.
  49. Oltra, A.
  50. Ramírez, J.
  51. Lomas, M.
  52. Barnadas, A.
  53. Sureda, M.
  54. Carabantes, F.
  55. Moreno, I.
  56. Moreno, A.L.
  57. Show all authors +
Journal:
Breast Cancer Research and Treatment

ISSN: 1573-7217 0167-6806

Year of publication: 2019

Volume: 177

Issue: 1

Pages: 115-125

Type: Article

DOI: 10.1007/S10549-019-05296-8 GOOGLE SCHOLAR

Sustainable development goals